Affiliation:
1. Department of Pharmacology, Escola Paulista de Medicina, Universidade Federal de São Paulo, Rua Pedro de Toledo,
669, Vila Clementino, São Paulo, SP, Postal Code: 04039-032, Brazil
Abstract
Background:
The hypothesis that a dyshomeostasis of Ca2+ increases the incidence of dementia
has been established. Several discoveries have emphasized the concept that a decrease in the
excess of Ca2+ could be an interesting pharmacological target to alleviate dementia symptoms. Aging
along with a healthy brain can be supported by daily exercise, self-control in caloric ingestion, and participation
in intellectually challenging events. These lifestyle factors may alleviate the excess of Ca2+
resulting from a Ca2+ dyshomeostasis. Curiously, epidemiological and clinical studies have also reported
a clinical relationship between hypertension, diabetes, and other inflammatory processes, and a higher
risk of cognition decline. Considering the cumulative data from the scientific literature, including
data of high evidence such as meta-analysis and systematic reviews, we can now link a Ca2+ dyshomeostasis
as an upstream factor for hypertension, diabetes and other inflammatory processes, and dementia.
Several reports have also indicated that increasing cAMP levels may induce neuroprotective outcomes,
thus alleviating dementia symptoms.
Methods:
With these concepts in mind, we found that the pharmacological manipulation of Ca2+/cAMP
signalling could be a novel plausible target to treat dementia. This article puts together fundamental
concepts and current therapies to treat dementia, including novel therapeutics coming from the pharmacological
manipulation of Ca2+/cAMP signalling.
Results:
Then, combined with improvements in the lifestyle issues, these novel therapeutics may allow
sustained improvements in the life quality of age-related neurological patients.
Conclusions:
In addition, considering coronavirus disease 2019 (COVID-19) is a rapidly evolving
field, this article also reviewed recent reports about Ca2+ channel blockers' role in restoring Ca2+ signalling
disruption due to COVID-19. Finally, this article also presents a timeline of the major events in
Ca2+/cAMP signaling.
Publisher
Bentham Science Publishers Ltd.
Subject
Neurology (clinical),Neurology
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献